Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Prostate Cancer

Free Subscription Articles published in Eur Urol Retrieve available abstracts of 263 articles: HTML format Text format

Single Articles

March 2012
1. OELKE M
   Re: dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.
   Eur Urol. 2012;61:624-5.
   PubMed     Text format     Related articles   
   
   
   
   
2. MOYAD MA
   Re: a prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
   Eur Urol. 2012;61:623-4.
   PubMed     Text format     Related articles   
   
   
   
   
3. SCHELLHAMMER P
   Re: prediction of erectile function following treatment for prostate cancer.
   Eur Urol. 2012;61:622.
   PubMed     Text format     Related articles   
   
   
   
   
4. DELONGCHAMPS NB , Zerbib M
   Re: role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.
   Eur Urol. 2012;61:622-3.
   PubMed     Text format     Related articles   
   
   
   
   February 2012
5. SCHMID HP , Theiler R
   Re: economic evaluation of denosumab compared with zoledronic Acid in hormone-refractory prostate cancer patients with bone metastases.
   Eur Urol. 2012;61:427-8.
   PubMed     Text format     Related articles   
   
   
   
   
6. SCHRODER FH
   Re: screening for prostate cancer: a review of the evidence for the u.s. Preventive services task force.
   Eur Urol. 2012;61:423-4.
   PubMed     Text format     Related articles   
   
   
   
   January 2012
7. KWIATKOWSKI M , Klotz L, Hugosson J, Recker F, et al
   Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer.
   Eur Urol. 2012.
   PubMed     Text format     Related articles   
   
   
   
   
8. CHADE DC , Eastham J, Graefen M, Hu JC, et al
   Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature.
   Eur Urol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. WU GH , Auvinen A, Yen AM, Hakama M, et al
   The Impact of Interscreening Interval and Age on Prostate Cancer Screening With Prostate-Specific Antigen.
   Eur Urol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. TODENHOFER T , Schwentner C, Stenzl A
    Personalized Treatment of Prostate Cancer Based on Inherited Variations of Steroid Pathway-Related Genes.
    Eur Urol. 2012.
    PubMed     Text format     Related articles   
    
    
    
    
11. PATEL A
    Re: office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population.
    Eur Urol. 2012;61:223-4.
    PubMed     Text format     Related articles   
    
    
    
    December 2011
12. JONIAU S , Van den Bergh L, Peeters C, Haustermans K, et al
    Nodal Staging in Prostate Cancer: Still an Unresolved Issue.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
13. ORSTED DD , Nordestgaard BG, Jensen GB, Schnohr P, et al
    Reply from Authors re: Stacy Loeb. Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening. Eur Urol. In press. DOI: 10.1016/j.eururo.2011.11.050.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
14. AGARWAL N , Sonpavde G, Sternberg CN
    Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. AUDET-WALSH E , Bellemare J, Lacombe L, Fradet Y, et al
    The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. THOMPSON IM , Ankerst DP
    The Benefits of Risk Assessment Tools for Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
17. VAN DER POEL HG , Brouwer OR, van den Berg NS, Buckle T, et al
    Reply to K. Polom, D. Murawa, W. Polom's Letter to the Editor re: Henk G. van der Poel, Tessa Buckle, Oscar R. Brouwer, Renato A. Valdes Olmos, Fijs W.B. van Leeuwen. Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Pros
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
18. POLOM K , Murawa D, Polom W
    Re: Henk G. van der Poel, Tessa Buckle, Oscar R. Brouwer, Renato A. Valdes Olmos, Fijs W.B. van Leeuwen. Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrat
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
19. CAI T , D'Elia C, Detti B
    Re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. Eur Urol. In press. doi:10.101
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
20. VAN HEMELRIJCK M , Stattin P, Adolfsson J
    Reply to Tommaso Cai, Carolina D'Elia, and Beatrice Detti's Letter to the Editor re: Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, et al. Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
21. GHADJAR P , Aebersold DM
    Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. In press. DOI:10.1016/j.eururo.2011.10.010.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
22. LOEB S
    Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
23. BRIGANTI A , Joniau S, Gontero P, Abdollah F, et al
    Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. PARKER C
    Re: radiotherapy and short-term androgen deprivation for localized prostate cancer.
    Eur Urol. 2011;60:1306.
    PubMed     Text format     Related articles   
    
    
    
    
25. LOEB S , Trock BJ
    Re: Randomised Prostate Cancer Screening Trial: 20 Year Follow-up.
    Eur Urol. 2011;60:1306-7.
    PubMed     Text format     Related articles   
    
    
    
    November 2011
26. ZHU X , Albertsen PC, Andriole GL, Roobol MJ, et al
    Risk-Based Prostate Cancer Screening.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. HEIDENREICH A
    Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymphadenectomy: Optimizing a Risk-Adapted Surgical Approach.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
28. ROOBOL MJ , van Vugt HA, Loeb S, Zhu X, et al
    Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. ORSTED DD , Nordestgaard BG, Jensen GB, Schnohr P, et al
    Prostate-Specific Antigen and Long-Term Prediction of Prostate Cancer Incidence and Mortality in the General Population.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. ARMSTRONG AJ , Eisenberger MA, Halabi S, Oudard S, et al
    Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. BRIGANTI A , Abdollah F, Nini A, Suardi N, et al
    Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. FROEHNER M
    Re: Firas Abdollah, Maxine Sun, Jan Schmitges, et al. Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
33. ABDOLLAH F , Sun M, Montorsi F, Karakiewicz PI, et al
    Reply to Michael Froehner's Letter to the Editor re: Firas Abdollah, Maxine Sun, Jan Schmitges, et al. Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
34. BRIGANTI A , Larcher A, Abdollah F, Capitanio U, et al
    Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. KLEIN RJ , Hallden C, Gupta A, Savage CJ, et al
    Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. CALISKAN S
    Re: Guillaume Ploussard, Alexandre de la Taille, Younes Bayoud, et al. The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance. Eur Urol. In press. DOI:10.1016/j.eururo.2011.07.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
37. GUAZZONI G , Lazzeri M, Nava L, Lughezzani G, et al
    Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. PLOUSSARD G
    Reply to Selahattin Caliskan's Letter to the Editor re: Guillaume Ploussard, Alexandre de la Taille, Younes Bayoud, et al. The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillanc
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
39. MCLEOD DG , Dobi A
    Re: Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer.
    Eur Urol. 2011;60:1123.
    PubMed     Text format     Related articles   
    
    
    
    
40. VAN CANGH PJ
    Re: the risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention.
    Eur Urol. 2011;60:1122.
    PubMed     Text format     Related articles   
    
    
    
    
41. JONIAU S , Spahn M
    Re: Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
    Eur Urol. 2011;60:1121-2.
    PubMed     Text format     Related articles   
    
    
    
    October 2011
42. SONPAVDE G , Di Lorenzo G, Higano CS, Kantoff PW, et al
    The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. STEPHENSON AJ , Bolla M, Briganti A, Cozzarini C, et al
    Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. NAJARI BB , Rink M, Graefen M, Shariat SF, et al
    Does Low-Risk Prostate Cancer Detection Change With Repeat Biopsies?
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
45. BUDAUS L , Bolla M, Bossi A, Cozzarini C, et al
    Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. JONIAU S , Abrahamsson PA, Bellmunt J, Figdor C, et al
    Current Vaccination Strategies for Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. RICHIE JP
    Re: abiraterone and increased survival in metastatic prostate cancer.
    Eur Urol. 2011;60:871.
    PubMed     Text format     Related articles   
    
    
    
    
48. COOPERBERG MR
    Re: radical prostatectomy versus watchful waiting in early prostate cancer.
    Eur Urol. 2011;60:868-9.
    PubMed     Text format     Related articles   
    
    
    
    
49. ALTWEIN JE
    Re: association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery.
    Eur Urol. 2011;60:868.
    PubMed     Text format     Related articles   
    
    
    
    
50. LINTON KD , Catto JW
    Re: comorbidity and mortality results from a randomised prostate cancer screening trial.
    Eur Urol. 2011;60:867.
    PubMed     Text format     Related articles   
    
    
    
    
51. SCATTONI V , Raber M, Capitanio U, Abdollah F, et al
    The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme.
    Eur Urol. 2011;60:834-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. OST P , Lumen N, Goessaert AS, Fonteyne V, et al
    High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
    Eur Urol. 2011;60:842-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
53. HINEV AI , Hadjiev VI, Kolev NH
    Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
54. VAN HEMELRIJCK M , Garmo H, Holmberg L, Stattin P, et al
    Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. MOROTE J , Planas J
    Antihypertensive Drugs and the Risk of Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
56. TOMBAL B
    Hormone Therapy for Prostate Cancer: What Have We Done With Charles Huggins' Legacy?
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
57. BOLLA M
    Intermediate- and High-Risk Prostate Cancer: A Plea for High-Dose, High-Precision Intensity-Modulated Radiotherapy With a Modulated Duration of Androgen Deprivation Therapy.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
58. ROZET F , Mongiat-Artus P
    Re: Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
    Eur Urol. 2011;60:598-9.
    PubMed     Text format     Related articles   
    
    
    
    
59. VAN DEN BERGH RC
    Re: delay of surgery in men with low-risk prostate cancer.
    Eur Urol. 2011;60:597-8.
    PubMed     Text format     Related articles   
    
    
    
    
60. PLOUSSARD G , Mongiat-Artus P
    Re: active surveillance program for prostate cancer: an update of the johns hopkins experience.
    Eur Urol. 2011;60:597.
    PubMed     Text format     Related articles   
    
    
    
    
61. DENIS L
    Prostate Cancer Units: The Patients' Perspective.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
62. SCHMITGES J , Trinh QD, Abdollah F, Sun M, et al
    A population-based analysis of temporal perioperative complication rates after minimally invasive radical prostatectomy.
    Eur Urol. 2011;60:564-71.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. MALIK RD , Goldberg JD, Hochman T, Lepor H, et al
    Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Eur Urol. 2011;60:548-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. FULLER A , Pautler SE
    Additional evidence for improved functional outcomes following robot-assisted radical prostatectomy.
    Eur Urol. 2011;60:420-1.
    PubMed     Text format     Related articles   
    
    
    
    
65. KOWALCZYK KJ , Huang AC, Hevelone ND, Lipsitz SR, et al
    Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes.
    Eur Urol. 2011;60:536-47.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. KIM SC , Song C, Kim W, Kang T, et al
    Factors determining functional outcomes after radical prostatectomy: robot-assisted versus retropubic.
    Eur Urol. 2011;60:413-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
67. AZOULAY L , Yin H, Benayoun S, Renoux C, et al
    Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. HAMBROCK T , Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, et al
    Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging-Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. AUPRICH M , Bjartell A, Chun FK, de la Taille A, et al
    Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
70. ZELEFSKY MJ , Pei X, Chou JF, Schechter M, et al
    Dose Escalation for Prostate Cancer Radiotherapy: Predictors of Long-Term Biochemical Tumor Control and Distant Metastases-Free Survival Outcomes.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. STENZL A
    Salvage Lymph Node Dissection in Recurrent Prostate Cancer Patients.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
72. GOMELLA LG
    The Prostate Cancer Unit: A Multidisciplinary Approach for Which the Time Has Arrived.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
73. PAGLIARULO V , Bracarda S, Eisenberger MA, Mottet N, et al
    Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. BJARTELL A
    Circulating Tumour Cells as Surrogate Biomarkers in Castration-Resistant Prostate Cancer Trials.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
75. VALDAGNI R
    Prostate Cancer Units: Has the Time Come to Discuss This Thorny Issue and Promote their Establishment in Europe?
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
76. COZZARINI C
    Low-dose-rate Brachytherapy, Radical Prostatectomy, or External-beam Radiation Therapy for Localised Prostate Carcinoma: The Growing Dilemma.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
77. FANTI S , Krause B, Weber W, Castellucci P, et al
    Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572-83.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
78. MOTTET N , Bellmunt J, Bolla M, Joniau S, et al
    Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prosta
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
79. VAN LEEUWEN PJ , Roobol MJ, Kranse R, Zappa M, et al
    Toward an Optimal Interval for Prostate Cancer Screening.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. SHEN Y , Ye D
    Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer. Eur Urol. In press. doi:10.1016/j.eururo.2011.06.034.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
81. SONPAVDE G , Pond GR, Armstrong AJ
    Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
82. LU-YAO GL
    Re: active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
    Eur Urol. 2011;60:393.
    PubMed     Text format     Related articles   
    
    
    
    
83. CATHCART P , Costello A
    Re: comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Eur Urol. 2011;60:393-4.
    PubMed     Text format     Related articles   
    
    
    
    
84. PATEL VR , Sivaraman A
    Re: David R. Yates, Morgan Roupret, Marc-Olivier Bitker, Christophe Vaessen. To infinity and beyond: the robotic toy story. Eur Urol 2011;60:263-5.
    Eur Urol. 2011;60:266-7.
    PubMed     Text format     Related articles   
    
    
    
    
85. GRAEFEN M
    Salvage radical prostatectomy in 2011: an established therapeutic option?
    Eur Urol. 2011;60:211-3.
    PubMed     Text format     Related articles   
    
    
    
    
86. NGUYEN CT , Kattan MW
    How to tell if a new marker improves prediction.
    Eur Urol. 2011;60:226-8.
    PubMed     Text format     Related articles   
    
    
    
    
87. YATES DR , Roupret M, Bitker MO, Vaessen C, et al
    To infinity and beyond: the robotic toy story.
    Eur Urol. 2011;60:263-5.
    PubMed     Text format     Related articles   
    
    
    
    
88. GODOY G , Chong KT, Cronin A, Vickers A, et al
    Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.
    Eur Urol. 2011;60:195-201.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
89. ORSTED DD , Bojesen SE, Nielsen SF, Nordestgaard BG, et al
    Reply from Authors re: Ryan P. Kopp, Stephen J. Freedland, J. Kellogg Parsons. Associations of Benign Prostatic Hyperplasia With Prostate Cancer: The Debate Continues. Eur Urol. In press. doi:10.1016/j.eururo.2011.07.005.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
90. PLOUSSARD G , de la Taille A, Bayoud Y, Durand X, et al
    The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. LIU Y , Hu F, Li D, Wang F, et al
    Does Physical Activity Reduce the Risk of Prostate Cancer? A Systematic Review and Meta-analysis.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
92. QIN X , Ye D
    Re: Chade DC, Shariat SF, Cronin AM, et al. Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration. Eur Urol 2011;60:205-10.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
93. DANILA DC , Anand A, Sung CC, Heller G, et al
    TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. BRAILLON A
    Re: Beltran H, Beer TM, Carducci MA, et al. New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. Eur Urol 2011;60:279-90.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
95. LINTON KD , Catto JW
    Gastrointestinal Toxicity Following Radiotherapy for Prostate Cancer: A Ring of Fire.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
96. KOPP RP , Freedland SJ, Parsons JK
    Associations of Benign Prostatic Hyperplasia With Prostate Cancer: The Debate Continues.
    Eur Urol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
97. KAKEHI Y
    Re: prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
    Eur Urol. 2011;60:178-9.
    PubMed     Text format     Related articles   
    
    
    
    
98. ROOBOL MJ
    Re: prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    Eur Urol. 2011;60:177-8.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
99. ABDOLLAH F , Sun M, Schmitges J, Tian Z, et al
    Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort.
    Eur Urol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. KALIN M , Cima I, Schiess R, Fankhauser N, et al
     Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. PEINEMANN F , Grouven U, Bartel C, Sauerland S, et al
     Permanent Interstitial Low-Dose-Rate Brachytherapy for Patients with Localised Prostate Cancer: A Systematic Review of Randomised and Nonrandomised Controlled Clinical Trials.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
102. ORSTED DD , Bojesen SE, Nielsen SF, Nordestgaard BG, et al
     Association of Clinical Benign Prostate Hyperplasia with Prostate Cancer Incidence and Mortality Revisited: A Nationwide Cohort Study of 3 009 258 Men.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. JERONIMO C , Bastian PJ, Bjartell A, Carbone GM, et al
     Epigenetics in Prostate Cancer: Biologic and Clinical Relevance.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. POND GR , Armstrong AJ, Wood BA, Brookes M, et al
     Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. CORNU JN , Cussenot O
     Reply to Giuseppe Lippi's Letter to the Editor re: Jean-Nicolas Cornu, Geraldine Cancel-Tassin, Valerie Ondet, et al. Olfactory Detection of Prostate Cancer by Dogs Sniffing Urine: A Step Forward in Early Diagnosis. Eur Urol 2011;59:197-201.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
106. LIPPI G
     Re: Jean-Nicolas Cornu, Geraldine Cancel-Tassin, Valerie Ondet, et al. Olfactory Detection of Prostate Cancer by Dogs Sniffing Urine: A Step Forward in Early Diagnosis. Eur Urol 2011;59:197-201.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
107. KIM S , Shen S, Moore DF, Shih W, et al
     Late Gastrointestinal Toxicities Following Radiation Therapy for Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
108. KLIMENT J
     Re: Salvage Therapy With Bicalutamide 150mg in Nonmetastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2011;59:1066-7.
     PubMed     Text format     Related articles   
     
     
     
     
109. KATZ AE , Capodice JL
     Re: acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
     Eur Urol. 2011;59:1066.
     PubMed     Text format     Related articles   
     
     
     
     
110. AKRE O , Garmo H, Adolfsson J, Lambe M, et al
     Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
111. GUILLONNEAU BD , Fizazi K
     Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news?
     Eur Urol. 2011;59:900-1.
     PubMed     Text format     Related articles   
     
     
     
     
112. BOORJIAN SA , Thompson RH, Tollefson MK, Rangel LJ, et al
     Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
     Eur Urol. 2011;59:893-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     May 2011
113. PLOUSSARD G , Epstein JI, Montironi R, Carroll PR, et al
     The Contemporary Concept of Significant Versus Insignificant Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
114. ZHU X , van Leeuwen PJ, Bul M, Otto SJ, et al
     Disease-Specific Survival of Men With Prostate Cancer Detected During the Screening Interval: Results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam After 11 Years of Follow-Up.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
115. GUAZZONI G , Nava L, Lazzeri M, Scattoni V, et al
     Reply from Authors re: Carvell T. Nguyen, Michael W. Kattan. How to Tell If a New Marker Improves Prediction. Eur Urol. In press. doi:10.1016/j.eururo.2011.04.029 and re: Monique J. Roobol. Prostate Cancer Biomarkers to Improve Risk Stratification: Is
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
116. BELTRAN H , Beer TM, Carducci MA, de Bono J, et al
     New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
117. NEPPLE KG , Kibel AS
     Re: active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
     Eur Urol. 2011;59:883-4.
     PubMed     Text format     Related articles   
     
     
     
     
118. ALBERTSEN P
     Re: active surveillance compared with initial treatment in men with low-risk prostate cancer: a decision analysis.
     Eur Urol. 2011;59:882-3.
     PubMed     Text format     Related articles   
     
     
     
     
119. KLINGLER C
     Re: the influence of family history on prostate cancer risk: implications for clinical management.
     Eur Urol. 2011;59:881-2.
     PubMed     Text format     Related articles   
     
     
     
     
120. MARBERGER M
     Is robot-assisted radical prostatectomy safer than other radical prostatectomy techniques?
     Eur Urol. 2011;59:699-700.
     PubMed     Text format     Related articles   
     
     
     
     
121. AGARWAL PK , Sammon J, Bhandari A, Dabaja A, et al
     Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients.
     Eur Urol. 2011;59:684-98.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
122. EASTHAM JA , Scardino PT
     The devil is in the details.
     Eur Urol. 2011;59:708-9.
     PubMed     Text format     Related articles   
     
     
     
     
123. CATTO JW , Alcaraz A, Bjartell AS, De Vere White R, et al
     MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
     Eur Urol. 2011;59:671-81.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
124. PATEL VR , Sivaraman A, Coelho RF, Chauhan S, et al
     Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy.
     Eur Urol. 2011;59:702-7.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     April 2011
125. SONPAVDE G , Attard G, Bellmunt J, Mason MD, et al
     The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
126. ROOBOL MJ
     Prostate Cancer Biomarkers to Improve Risk Stratification: Is Our Knowledge of Prostate Cancer Sufficient to Spare Prostate Biopsies Safely?
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
127. YATES DR , Roupret M
     Small Renal Mass and Low-Risk Prostate Cancer: Any More for Active Surveillance?
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
128. DE NUNZIO C , Kramer G, Marberger M, Montironi R, et al
     The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
129. GUAZZONI G , Nava L, Lazzeri M, Scattoni V, et al
     Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
130. GODOY G , Coleman JA
     Reply of Authors re: R. Jeffrey Karnes. To What Extent Can We Predict Prostate Cancer Lymph Node Involvement? Eur Urol. In press. doi:10.1016/j.eururo.2011.02.025.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
131. JOCHAM D , Sommerauer M
     Re: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial.
     Eur Urol. 2011;59:659.
     PubMed     Text format     Related articles   
     
     
     
     
132. ITO K
     RE: Mortality Results From the Goteborg Randomised Population-Based Prostate-Cancer Screening Trial.
     Eur Urol. 2011;59:659-61.
     PubMed     Text format     Related articles   
     
     
     
     
133. BEUZEBOC P
     Re: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
     Eur Urol. 2011;59:658.
     PubMed     Text format     Related articles   
     
     
     
     
134. CUSSENOT O , Comperat E, Bitker MO, Roupret M, et al
     From active surveillance to the concept of secondary prevention.
     Eur Urol. 2011;59:568-71.
     PubMed     Text format     Related articles   
     
     
     
     
135. KETO CJ , Freedland SJ
     A risk-stratified approach to prostate-specific antigen screening.
     Eur Urol. 2011;59:506-8.
     PubMed     Text format     Related articles   
     
     
     
     
136. PRESTON MA , Carriere M, Raju G, Morash C, et al
     The prognostic significance of capsular incision into tumor during radical prostatectomy.
     Eur Urol. 2011;59:613-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     March 2011
137. VAN DER POEL HG , Buckle T, Brouwer OR, Valdes Olmos RA, et al
     Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrated Functional Imaging Approach Using a Multimodal Tracer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
138. BOORMANS JL , Porkka K, Visakorpi T, Trapman J, et al
     Confirmation of the Association of TMPRSS2(exon 0):ERG Expression and a Favorable Prognosis of Primary Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
139. CAPITANIO U , Cheng L, Lopez-Beltran A, Scarpelli M, et al
     The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
140. BARENTSZ J , Dickinson L, Sciarra A
     Re: Axel Heidenreich. Consensus Criteria for the Use of Magnetic Resonance Imaging in the Diagnosis and Staging of Prostate Cancer: Not Ready for Routine Use. Eur Urol 2011;59:495-7.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
141. CHADE DC , Shariat SF, Cronin AM, Savage CJ, et al
     Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
142. BJARTELL A
     Genetic Markers and the Risk of Developing Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
143. KOBUS T , Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, et al
     In Vivo Assessment of Prostate Cancer Aggressiveness Using Magnetic Resonance Spectroscopic Imaging at 3 T with an Endorectal Coil.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
144. IZUMI K , Zheng Y, Miyamoto H
     Eppin Expression in Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
145. JANETSCHEK G
     Re: five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation.
     Eur Urol. 2011;59:467.
     PubMed     Text format     Related articles   
     
     
     
     
146. BASTIAN PJ
     Does the surgeon really matter? Functional results following radical prostatectomy.
     Eur Urol. 2011;59:323-4.
     PubMed     Text format     Related articles   
     
     
     
     
147. TRPKOV K , Yilmaz A
     Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol 2010;58:369
     Eur Urol. 2011;59:e5-6.
     PubMed     Text format     Related articles   
     
     
     
     
148. VICKERS A , Savage C, Bianco F, Mulhall J, et al
     Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center.
     Eur Urol. 2011;59:317-22.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     February 2011
149. SCIARRA A , Barentsz J, Bjartell A, Eastham J, et al
     Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
150. BRIGANTI A , Karnes RJ, Pozzo LF, Cozzarini C, et al
     Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2-4 pN+ Prostate Cancer: Results of a Matched Analysis.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
151. KARNES RJ
     To What Extent Can We Predict Prostate Cancer Lymph Node Involvement?
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
152. ABDOLLAH F , Sun M, Montorsi F, Karakiewicz PI, et al
     Reply to Charles B. Simone II, Charles B. Simone's Letter to the Editor re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. Eur
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
153. SIMONE CB 2ND , Simone CB
     Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. Eur Urol 2011;59:88-95.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
154. TERRONE C
     Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
     Eur Urol. 2011;59:304-5.
     PubMed     Text format     Related articles   
     
     
     
     
155. FREEDLAND SJ , Andriole GL
     Making an imperfect marker better.
     Eur Urol. 2011;59:194-6.
     PubMed     Text format     Related articles   
     
     
     
     
156. SOORIAKUMARAN P , Tewari A
     Dorsal vein complex control after apical dissection results in low apical positive surgical margins, but other surgical maneuvers are required to optimize early continence recovery.
     Eur Urol. 2011;59:222-3.
     PubMed     Text format     Related articles   
     
     
     
     January 2011
157. CHA EK , Shariat SF
     The Use of 5alpha-Reductase Inhibitors for the Prevention and Treatment of Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
158. MOTTET N , Bellmunt J, Bolla M, Joniau S, et al
     EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
159. HEIDENREICH A
     Consensus Criteria for the Use of Magnetic Resonance Imaging in the Diagnosis and Staging of Prostate Cancer: Not Ready for Routine Use.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
160. ALY M , Wiklund F, Xu J, Isaacs WB, et al
     Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
161. BUDIHARTO T , Joniau S, Lerut E, Van den Bergh L, et al
     Prospective Evaluation of (11)C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
162. JONES JS
     Radiorecurrent Prostate Cancer: An Emerging and Largely Mismanaged Epidemic.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
163. SCHULMAN C
     Reply to Ruth E. Langley, Patricia Price and Paul D. Abel's Letter to the Editor re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675-91.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
164. LANGLEY RE , Price P, Abel PD
     Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675-91.
     Eur Urol. 2011.
     PubMed     Text format     Related articles   
     
     
     
     
165. BUL M , van Leeuwen PJ, Zhu X, Schroder FH, et al
     Prostate Cancer Incidence and Disease-Specific Survival of Men with Initial Prostate-Specific Antigen Less Than 3.0ng/ml Who Are Participating in ERSPC Rotterdam.
     Eur Urol. 2011.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
166. MENON M
     Robot-assisted radical prostatectomy: is the dust settling?
     Eur Urol. 2011;59:7-9.
     PubMed     Text format     Related articles   
     
     
     
     
167. DI PIERRO GB , Baumeister P, Stucki P, Beatrice J, et al
     A prospective trial comparing consecutive series of open retropubic and robot-assisted laparoscopic radical prostatectomy in a centre with a limited caseload.
     Eur Urol. 2011;59:1-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
168. CORNEL EB
     Re: Fritz H. Schroder, Monique J. Roobol. The REDUCE Trial. Eur Urol 2010;58:253-255.
     Eur Urol. 2011;59:e1.
     PubMed     Text format     Related articles   
     
     
     
     December 2010
169. DUIJVESZ D , Luider T, Bangma CH, Jenster G, et al
     Exosomes as Biomarker Treasure Chests for Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
170. FINELLI A , Trottier G, Lawrentschuk N, Sowerby R, et al
     Impact of 5alpha-Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
171. WILLIAMS AK , Martinez CH, Lu C, Ng CK, et al
     Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
172. JUNG K , Miller K, Wirth M, Albrecht M, et al
     Bone Turnover Markers as Predictors of Mortality Risk in Prostate Cancer Patients with Bone Metastases Following Treatment with Zoledronic Acid.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
173. DICKINSON L , Ahmed HU, Allen C, Barentsz JO, et al
     Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
174. PLOUSSARD G , Durand X, Xylinas E, Moutereau S, et al
     Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
175. ROOBOL MJ
     Reply to David Connolly, Rachel Hutton, Patrick F. Keane's Letter to the Editor re: Monique J. Roobol, Fritz H. Schroder, Pim van Leeuwen, et al. Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
176. CONNOLLY D , Hutton R, Keane PF
     Re: Monique J. Roobol, Fritz H. Schroder, Pim van Leeuwen, et al. Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic Test. Eur Urol 2010;58
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
177. DJAVAN B
     Screening for Prostate Cancer: Practical Analysis of the ESRPC and PLCO Trials.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
178. CLARKE NW
     Is Population Screening for Prostate Cancer Good or Bad?
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
179. VILLERS A , Ouzzane A
     Re: three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.
     Eur Urol. 2010;58:941-2.
     PubMed     Text format     Related articles   
     
     
     
     
180. HAMDY FC
     Re: mortality results from the goteborg randomised population-based prostate-cancer screening trial.
     Eur Urol. 2010;58:940-1.
     PubMed     Text format     Related articles   
     
     
     
     
181. WIRTH MP , Froehner M
     Re: mortality results from the goteborg randomised population-based prostate-cancer screening trial.
     Eur Urol. 2010;58:939-40.
     PubMed     Text format     Related articles   
     
     
     
     
182. MARONI P , Theodorescu D
     Re: mortality results from the goteborg randomised population-based prostate-cancer screening trial.
     Eur Urol. 2010;58:938-9.
     PubMed     Text format     Related articles   
     
     
     
     November 2010
183. THOMPSON IM JR , Leach RJ, Ankerst DP
     Prostate Cancer Detection: A View of the Future.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
184. NGUYEN PN , Violette P, Chan S, Tanguay S, et al
     A Panel of TMPRSS2:ERG Fusion Transcript Markers for Urine-Based Prostate Cancer Detection with High Specificity and Sensitivity.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
185. ROEHRBORN CG , Andriole GL, Wilson TH, Castro R, et al
     Effect of Dutasteride on Prostate Biopsy Rates and the Diagnosis of Prostate Cancer in Men with Lower Urinary Tract Symptoms and Enlarged Prostates in the Combination of Avodart and Tamsulosin Trial.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
186. BASTIAN PJ
     Re: prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
     Eur Urol. 2010;58:796.
     PubMed     Text format     Related articles   
     
     
     
     
187. VAN DER KWAST T
     Re: the index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer.
     Eur Urol. 2010;58:796-7.
     PubMed     Text format     Related articles   
     
     
     
     
188. GAUTAM G , Steinberg GD
     Re: impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.
     Eur Urol. 2010;58:794.
     PubMed     Text format     Related articles   
     
     
     
     October 2010
189. BJARTELL AS
     Dogs Sniffing Urine: A Future Diagnostic Tool or a Way to Identify New Prostate Cancer Markers?
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
190. HEIDENREICH A , Bellmunt J, Bolla M, Joniau S, et al
     EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
191. ROOBOL MJ
     Is Prostate Cancer Screening Bad or Good? Summary of a Debate at the Innovation in Urology Meeting, September 17-19, 2010, Milan, Italy.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
192. AUPRICH M , Chun FK, Ward JF, Pummer K, et al
     Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
193. CORNU JN , Cancel-Tassin G, Ondet V, Girardet C, et al
     Olfactory Detection of Prostate Cancer by Dogs Sniffing Urine: A Step Forward in Early Diagnosis.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
194. VAN LEEUWEN PJ , Kolble K, Huland H, Hambrock T, et al
     Prostate Cancer Detection and Dutasteride: Utility and Limitations of Prostate-Specific Antigen in Men with Previous Negative Biopsies.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
195. ABDOLLAH F , Sun M, Thuret R, Jeldres C, et al
     A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
196. PERDONA S , Cavadas V, Di Lorenzo G, Damiano R, et al
     Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
197. GANZER R , Blana A
     Do We Have Enough Evidence to Recommend the Routine Use of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer?
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
198. SCHENK EA
     Words of wisdom. Re: overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
     Eur Urol. 2010;58:632-3.
     PubMed     Text format     Related articles   
     
     
     
     
199. BOSLAND MC , Cremers RG, Kiemeney LA
     Words of wisdom. Re: effect of dutasteride on the risk of prostate cancer.
     Eur Urol. 2010;58:631-2.
     PubMed     Text format     Related articles   
     
     
     
     
200. SAGALOWSKY AL
     Words of wisdom. Re: androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Ra
     Eur Urol. 2010;58:630.
     PubMed     Text format     Related articles   
     
     
     
     
201. SMITH JA JR
     Words of wisdom. Re: androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Ra
     Eur Urol. 2010;58:629.
     PubMed     Text format     Related articles   
     
     
     
     
202. TOUIJER K
     Marketing versus science: a fight between necessary evil and stern good over the adoption of new technology in medicine.
     Eur Urol. 2010;58:522-4.
     PubMed     Text format     Related articles   
     
     
     
     
203. WHITE MA , Haber GP, Autorino R, Khanna R, et al
     Robotic laparoendoscopic single-site radical prostatectomy: technique and early outcomes.
     Eur Urol. 2010;58:544-50.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     September 2010
204. ABDOLLAH F , Sun M, Thuret R, Budaus L, et al
     Decreasing Rate and Extent of Lymph Node Staging in Patients Undergoing Radical Prostatectomy May Undermine the Rate of Diagnosis of Lymph Node Metastases in Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
205. ROOBOL MJ , Schroder FH, van Leenders GL, Hessels D, et al
     Performance of Prostate Cancer Antigen 3 (PCA3) and Prostate-Specific Antigen in Prescreened Men: Reproducibility and Detection Characteristics for Prostate Cancer Patients with High PCA3 Scores (>/=100).
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
206. ALBERTSEN P
     Further Support for Active Surveillance in the Management of Low-Volume, Low-Grade Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
207. WARMUTH M , Johansson T, Mad P
     Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
208. PICCHIO M , Briganti A, Fanti S, Heidenreich A, et al
     The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
209. SOORIAKUMARAN P , Tewari A
     Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al.
     Eur Urol. 2010;58:465-6.
     PubMed     Text format     Related articles   
     
     
     
     
210. FINLEY DS , Pouliot F, Pantuck A
     Words of wisdom. Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Kantoff PW, Schuetz TJ, Blumenstein BA, et al.
     Eur Urol. 2010;58:466.
     PubMed     Text format     Related articles   
     
     
     
     
211. MILLER K
     Words of wisdom. Re: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.
     Eur Urol. 2010;58:464-5.
     PubMed     Text format     Related articles   
     
     
     
     
212. OOSTERLINCK W
     Words of wisdom. Re: Increased risk of high-grade prostate cancer among infertile men. Walsh TJ, Shembri M, Turek PJ, et al.
     Eur Urol. 2010;58:463.
     PubMed     Text format     Related articles   
     
     
     
     
213. NEULANDER EZ , Wejsman Z
     Re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010;58:1-7.
     Eur Urol. 2010;58:e36.
     PubMed     Text format     Related articles   
     
     
     
     
214. GALFANO A , Ascione A, Grimaldi S, Petralia G, et al
     A new anatomic approach for robot-assisted laparoscopic prostatectomy: a feasibility study for completely intrafascial surgery.
     Eur Urol. 2010;58:457-61.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
215. OST P , Bossi A, De Meerleer G
     Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30.
     Eur Urol. 2010;58:e33.
     PubMed     Text format     Related articles   
     
     
     
     
216. MONTIRONI R , Cheng L, Lopez-Beltran A, Scarpelli M, et al
     Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports.
     Eur Urol. 2010;58:369-73.
     PubMed     Text format     Related articles   
     
     
     
     August 2010
217. SOLOWAY MS , Soloway CT, Eldefrawy A, Acosta K, et al
     Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for Treatment.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
218. ROVIGATTI U , Selli C, Bartoletti R
     Of Mice and Men-Viruses and Prostate Cancer: What Is the Next Step?
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
219. COLLESELLI D , Stenzl A, Schwentner C
     Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12-8.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
220. CROUZET S , Gelet A
     Reply from Authors re: Patrick J. Bastian. High-Intensity Focused Ultrasound for Localized Prostate Cancer: Ready for Prime Time? Eur Urol. In press. doi:10.1016/j.eururo.2010.08.003.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
221. STRANNE J , Johansson E, Nilsson A, Bill-Axelson A, et al
     Inguinal Hernia After Radical Prostatectomy for Prostate Cancer: Results From a Randomized Setting and a Nonrandomized Setting.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
222. BASTIAN PJ
     High-Intensity Focused Ultrasound for Localized Prostate Cancer: Ready for Prime Time?
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
223. JENTZMIK F , Stephan C, Jung K
     Reply to Amitha K Hewavitharana's Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
224. HEWAVITHARANA AK
     Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12-8.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
225. GOTTO GT , Cronin AM, Laudone VP
     Important Considerations in the Clinical Use of Preoperative Prostate Cancer Predictive Nomograms.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
226. SCIARRA A
     Words of wisdom. Re: Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Maxeiner A, Adkins CB, Zhang Y, et al. Prostate 2010;70:710-7.
     Eur Urol. 2010;58:315.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
227. KLOTZ L
     Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202.
     Eur Urol. 2010;58:313.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
228. LANGE PH
     Words of wisdom. Re: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Morris MJ, Huang D, Kelly WK, et al. Eur Urol 2009;56:237-44.
     Eur Urol. 2010;58:311-2.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
229. PAVONE-MACALUSO M
     Words of wisdom. Re: Does oral antiandrogen use before leuteinizing hormone-releasing therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Oh WK, Landrum MB, Lamont EB, et al. Urology 2010;75:642-7
     Eur Urol. 2010;58:314-5.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
230. MADERSBACHER S
     Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group. N Engl J Med 2010;362:1192-202.
     Eur Urol. 2010;58:312.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
231. VERHAGEN PC , Schroder FH, Collette L, Bangma CH, et al
     Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review.
     Eur Urol. 2010;58:261-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
232. SOLOWAY MS , Gorin MA, Katkoori D
     "Definitive therapy" for cancer: is our message clear?
     Eur Urol. 2010;58:256-7.
     PubMed     Text format     Related articles   
     
     
     
     
233. PUPPO P , Naselli A
     Re: Richard E. Hautmann, Oliver Hautmann, Born G. Volkmer, Stefan Hautmann. Nerve-sparing radical cystectomy: a new technique. Eur Urol Suppl 2010;9:428-432.
     Eur Urol. 2010;58:e26.
     PubMed     Text format     Related articles   
     
     
     
     
234. SCHRODER FH , Roobol MJ
     The REDUCE Trial.
     Eur Urol. 2010;58:253-5.
     PubMed     Text format     Related articles   
     
     
     
     
235. DREWA TA , Chlosta PL
     Re: Noel W. Clarke, Michael Marberger. The motion: GnRH antagonists are the new way forward in hormonal therapy. Eur Urol 2010;57:534-7.
     Eur Urol. 2010;58:e20.
     PubMed     Text format     Related articles   
     
     
     
     July 2010
236. FICARRA V , Novara G, Zattoni F
     The Role of the Prostate Cancer Antigen 3 (PCA3) Test for the Diagnosis of Prostate Cancer in the Era of Opportunistic Prostate-Specific Antigen Screening.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
237. ROOBOL MJ , Schroder FH
     Reply from Authors re: Vincenzo Ficarra, Giacomo Novara, Filiberto Zattoni, The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening, Eur Urol. In press.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
238. ENGEL J , Bastian PJ, Holzel D
     Reply to XiaoJian Qin and DingWei Ye's Letter to the Editor re: Jutta Engel, Patrick J. Bastian, Helmut Baur, et al. Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer. Eur Urol. In press. doi:10.1016/j.euru
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
239. QIN X , Ye D
     Re: Jutta Engel, Patrick J. Bastian, Helmut Baur, et al. Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer. Eur Urol 2010;57:754-61.
     Eur Urol. 2010.
     PubMed     Text format     Related articles   
     
     
     
     
240. ROOBOL MJ , Schroder FH, van Leeuwen P, Wolters T, et al
     Performance of the Prostate Cancer Antigen 3 (PCA3) Gene and Prostate-Specific Antigen in Prescreened Men: Exploring the Value of PCA3 for a First-line Diagnostic Test.
     Eur Urol. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
241. PLOUSSAR G , Mongiat-Artus P
     Re: clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
     Eur Urol. 2010;58:179-80.
     PubMed     Text format     Related articles   
     
     
     
     
242. JOSHI N , de Blok W, van Muilekom E, van der Poel H, et al
     Impact of posterior musculofascial reconstruction on early continence after robot-assisted laparoscopic radical prostatectomy: results of a prospective parallel group trial.
     Eur Urol. 2010;58:84-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
243. SPAHN M , Joniau S, Gontero P, Fieuws S, et al
     Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
     Eur Urol. 2010;58:1-7.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
244. LEE MC , Dong F, Stephenson AJ, Jones JS, et al
     The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy.
     Eur Urol. 2010;58:90-5.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
245. CULIG Z
     Editorial comment on: human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells.
     Eur Urol. 2010;58:171-2.
     PubMed     Text format     Related articles   
     
     
     
     
246. THALMANN GN , Rhee H, Sikes RA, Pathak S, et al
     Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.
     Eur Urol. 2010;58:162-71.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     June 2010
247. DJAVAN B
     Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
     Eur Urol. 2010;57:928-9.
     PubMed     Text format     Related articles   
     
     
     
     
248. LARRE S , Ronsin C, Irani J
     Immediate impact of ultrasound-guided prostate biopsies on PCA3 score.
     Eur Urol. 2010;57:1121-2.
     PubMed     Text format     Related articles   
     
     
     
     
249. CENTEMERO A , Rigatti L, Giraudo D, Lazzeri M, et al
     Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study.
     Eur Urol. 2010;57:1039-43.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
250. COELHO RF , Palmer KJ, Rocco B, Moniz RR, et al
     Early complication rates in a single-surgeon series of 2500 robotic-assisted radical prostatectomies: report applying a standardized grading system.
     Eur Urol. 2010;57:945-52.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
251. COELHO RF , Chauhan S, Orvieto MA, Palmer KJ, et al
     Predictive factors for positive surgical margins and their locations after robot-assisted laparoscopic radical prostatectomy.
     Eur Urol. 2010;57:1022-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     May 2010
252. SCHAEFER A , Jung K
     Re: MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
     Eur Urol. 2010;57:919.
     PubMed     Text format     Related articles   
     
     
     
     
253. GOMELLA LG
     Re: Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer.
     Eur Urol. 2010;57:915-6.
     PubMed     Text format     Related articles   
     
     
     
     
254. INCROCCI L
     Re: Time of decline in sexual function after external beam radiotherapy for prostate cancer.
     Eur Urol. 2010;57:916.
     PubMed     Text format     Related articles   
     
     
     
     
255. WIRTH MP , Froehner M
     Robot-assisted radical prostatectomy: the new gold standard?
     Eur Urol. 2010;57:750-1.
     PubMed     Text format     Related articles   
     
     
     
     
256. MOTTRIE AM
     The introduction of robot-assisted surgery in urologic practice: why is it so difficult?
     Eur Urol. 2010;57:747-9.
     PubMed     Text format     Related articles   
     
     
     
     
257. STUDER UE , Collette L, Sylvester R
     Can radical prostatectomy benefit patients despite the presence of regional metastases?
     Eur Urol. 2010;57:762-3.
     PubMed     Text format     Related articles   
     
     
     
     
258. MURPHY DG , Bjartell A, Ficarra V, Graefen M, et al
     Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications.
     Eur Urol. 2010;57:735-46.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     April 2010
259. MARKS LS , Huang J
     Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
     Eur Urol. 2010;57:727-8.
     PubMed     Text format     Related articles   
     
     
     
     
260. KATTAN MW
     Comparing prediction tools.
     Eur Urol. 2010;57:569-70.
     PubMed     Text format     Related articles   
     
     
     
     
261. KATTAN MW
     Classification and regression trees versus nomograms: a bone scan positivity example.
     Eur Urol. 2010;57:559-60.
     PubMed     Text format     Related articles   
     
     
     
     
262. VICKERS A
     Prediction models in urology: are they any good, and how would we know anyway?
     Eur Urol. 2010;57:571-3.
     PubMed     Text format     Related articles   
     
     
     
     
263. LUGHEZZANI G , Budaus L, Isbarn H, Sun M, et al
     Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy.
     Eur Urol. 2010;57:562-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: